Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-11
2010-12-14
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S405000, C544S406000
Reexamination Certificate
active
07851476
ABSTRACT:
Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazineits salts and solvates thereof are herein set forth, as are pharmaceutical compositions comprising the crystalline form(s), as well of methods of using the crystalline form(s) in the treatment of HIV and/or AIDS, and methods for obtaining such crystalline form(s).
REFERENCES:
patent: 3135794 (1964-06-01), Archer
patent: 4791104 (1988-12-01), Picciola et al.
patent: 5023265 (1991-06-01), Scherlock et al.
patent: 5124327 (1992-06-01), Greenlee et al.
patent: 5192770 (1993-03-01), Clark et al.
patent: 5413999 (1995-05-01), Vacca et al.
patent: 5424329 (1995-06-01), Boschelli et al.
patent: 5811432 (1998-09-01), Marfat et al.
patent: 6008231 (1999-12-01), Lebaut et al.
patent: 6172085 (2001-01-01), Ohkawa et al.
patent: 6232327 (2001-05-01), Nickel et al.
patent: 6469006 (2002-10-01), Blair et al.
patent: 6476034 (2002-11-01), Wang et al.
patent: 6573262 (2003-06-01), Wallace et al.
patent: 6632819 (2003-10-01), Wang et al.
patent: 6825201 (2004-11-01), Wang et al.
patent: 6900206 (2005-05-01), Kadow et al.
patent: 7037913 (2006-05-01), Wang et al.
patent: 7087610 (2006-08-01), Wang et al.
patent: 2002/0061892 (2002-05-01), Wang et al.
patent: 2003/0069266 (2003-04-01), Wang et al.
patent: 2003/0207910 (2003-11-01), Wang et al.
patent: 2003/0236277 (2003-12-01), Kadow et al.
patent: 2004/0063744 (2004-04-01), Wang et al.
patent: 2004/0063746 (2004-04-01), Regueiro-Ren et al.
patent: 2004/0110785 (2004-06-01), Wang et al.
patent: 2004/0186292 (2004-09-01), Wang et al.
patent: 2005/0075364 (2005-04-01), Yeung et al.
patent: 2005/0090522 (2005-04-01), Wang et al.
patent: 2005/0124623 (2005-06-01), Bender et al.
patent: 2005/0209246 (2005-09-01), Ueda et al.
patent: 2005/0215543 (2005-09-01), Lin et al.
patent: 2005/0215544 (2005-09-01), Lin et al.
patent: 2005/0215545 (2005-09-01), Lin et al.
patent: 2005/0267130 (2005-12-01), Ruediger et al.
patent: 2006/0100209 (2006-05-01), Gu et al.
patent: 2006/0100432 (2006-05-01), Matiskella et al.
patent: 2006/0142298 (2006-06-01), Kadow et al.
patent: 2007/0078141 (2007-04-01), Wang et al.
patent: 2007/0249579 (2007-10-01), Wang et al.
patent: 2007/0249624 (2007-10-01), Bachand et al.
patent: 0379314 (1990-07-01), None
patent: 0484071 (1992-05-01), None
patent: 0530907 (1993-03-01), None
patent: 1069111 (2001-01-01), None
patent: WO 93/01181 (1993-01-01), None
patent: WO 95/04742 (1995-02-01), None
patent: WO 96/11929 (1996-04-01), None
patent: WO 97/25350 (1997-07-01), None
patent: WO 98/28292 (1998-07-01), None
patent: WO 99/24065 (1999-05-01), None
patent: WO 00/00201 (2000-01-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/51984 (2000-09-01), None
patent: WO 00/71535 (2000-11-01), None
patent: WO 00/76521 (2000-12-01), None
patent: WO 01/22954 (2001-04-01), None
patent: WO 01/62255 (2001-08-01), None
patent: WO 02/04440 (2002-01-01), None
patent: WO 02/10152 (2002-02-01), None
patent: WO 02/62423 (2002-08-01), None
patent: WO 02/085301 (2002-10-01), None
patent: WO 03/041644 (2003-05-01), None
patent: WO 03/068221 (2003-08-01), None
patent: WO 03/082881 (2003-10-01), None
patent: WO 03/092695 (2003-11-01), None
patent: WO 03/103607 (2003-12-01), None
patent: WO 2004/000210 (2003-12-01), None
patent: WO 2004/011425 (2004-02-01), None
patent: WO 2004/043337 (2004-05-01), None
patent: WO 2005/016344 (2005-02-01), None
patent: WO 2005/121094 (2005-12-01), None
U.S. Appl. No. 11/748,699.
U.S. Appl. No. 11/749,445.
Heimbach, et al, “Absorption Rate Limit Considerations for Oral Phosphate Prodrugs,” Pharmaceutical Research, 20(6), pp. 848-856, 2003.
Stella, et al, Pharmacokinetics of Drug Targeting: Specific Implications for Targeting Via Prodrugs, Handbook of Experimental Pharmacology, Chapter 4, pp. 71-103, 1991.
Zhu, et al, “A One-Pot Synthesis of Nitrogen-Containing Heteroaryl α-Keto Amides from Heteroaryl Halides,” Tetrahedron Letters, 46(20), pp. 3587-3589, 2005.
Yin, et al., “Simulated PXRD Patterns in Studies of the Phase Composition and Thermal Behavior of Bulk Crystalline Solids,” American Pharmaceutical Review, 2003, 6, 2, pp. 80-85.
Hotoda, “Small-Molecule Inhibitors of HIV-1 Entry Via Chemokine Receptors,” Drugs of the Fututre, 24(12), pp. 1355-1362, 1999.
Sodroski, “HIV-1 Entry Inhibitors in the Side Pocket,” Cell, 9, pp. 243-246, 1999.
Blair, et al, “HIV-1 Entry-An Expanding Portal for Drug Discovery,” Drug Discovery Today, 5(5), pp. 183-194, 2000.
Font, et al, “Indoles and Pyridazinol[4,5-b]Indoles as Nonnucleoside Analog Inhibitors of HIV-1 Reverse Transcriptase,” Eur. J. Med. Chem., 30, pp. 963-971, 1995.
Romero, et al, J. Med. Chem., 36, pp. 1505-1508, 1993.
Young, et al, “2-Heterocyclic Indole-3-Sulfones as Inhibitors of HIV-1 Reverse Transcriptase,” Bioorg. Med. Chem. Lett., 5(5), pp. 491-496, 1995.
Genin, et al, “Synthesis and Bioactivity of Novel Bis(Heteroaryl)Piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships and Increased Metabolic Stability of Novel Substituted Pyridine Analogs,” J. Med. Chem., 39, pp. 5267-5275, 1996.
Silvestri, et al, Antiviral Chem. Chemother., 9, pp. 139-148, 1998.
Fredenhagen, et al, “Semicochllodinol A and B: Inhibitors of HIV-1 Protease and EGF-R Protein Tyrosine Kinease Related to Asterriquinones Produced by the Fungus Chrysosporium Merdarium,” J. of Antibiotics, 50, pp. 395-401, 1997.
Wang, et al., Org. Biol. Chem., 2005, 3, pp. 1781-1786.
Meanwell et al., Current Opinion in Drug Discovery and Development, 2003, 6, 4, pp. 451-461.
Dueweke, et al, “The Binding of a Novel Bisheteroarylpiperazine Mediates Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase,” J. Biol. Chem., 267(1), pp. 27-30, 1992.
Dueweke, et al, “U-90152, a Potent Inhibitor of Human Immunodeficiency Virus type 1 Replication,” Antimicrob. Agent, Chemother., 37(5), pp. 1127-1131, 1993.
Kato, et al, “New 5-HT3(Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Relationships of Azabicycloalkaneacetamide Derivatives,” Chem. Pharm. Bull., 43(8), pp. 1351-1357, 1995.
Levacher, et al, “Broadening in the Scope of NADH Models by Using Chiral and Non Chiral Pyrrolo [2,3-b]Pyridine Derivatives,” Tetrahedron, 47(3), pp. 429-440, 1991.
Resnyanskaya, et al, “A Simple Synthesis of 1-Acyl-3-Aryl-3H-Pyrrolo[2′,3′:4,5]Pyrimido[6,1-b]Benzothiazol-6-ium-2-olates: Betainic Derivatives of a Novel Heterocyclic System,” Synthesis, 18, pp. 2717-2724, 2002.
Chen Chung-Pin H.
Gao Qi
Gu Chong-Hui
Levons Jaquan Kalani
Parker Dawn DiGiugno
Bristol--Myers Squibb Company
Levis John F.
McDowell Brian
Wilson James O
LandOfFree
Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4236700